ESTRO 2024 - Abstract Book

S2107

Clinical - Sarcoma, skin cancer, melanoma

ESTRO 2024

1941

Poster Discussion

ONCOLOGICAL OUTCOMES OF NEOADJUVANT RADIOTHERAPY WITH RADIATIVE HYPERTHERMIA IN SOFT TISSUE SARCOMA

pasquale trecca 1 , michele fiore 1,2 , gabriele d'ercole 2 , gian marco petrianni 1 , pierluigi falco 1 , carlo greco 2 , edy ippolito 2,1 , sergio valeri 3 , bruno vincenzi 4,5 , sara ramella 2,1 1 Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Radiation Oncology, roma, Italy. 2 Università Campus Bio-Medico di Roma, Radiation Oncology, roma, Italy. 3 Fondazione Policlinico Universitario Campus Bio Medico di Roma, Surgery, roma, Italy. 4 Università Campus Bio-Medico di Roma, Medical Oncology, roma, Italy. 5 Fondazione Policlinico Universitario Campus Bio-Medico di Roma, Medical Onology, roma, Italy

Purpose/Objective:

This study aims to evaluate the oncological outcomes of patients with soft tissue sarcoma (STS) ofthe extremities and trunk who received neoadjuvant radiotherapy (RT),with or without chemotherapy,combined with radiative hyperthermia (HT)

Material/Methods:

A retrospective analysis was conducted on patientswho underwent RT and concomitant HT followed by surgery. All patients received VMAT radiotherapy witha total dose of 50 Gy in 25 fractions.HT sessions were performed immediately after RT and within threehours of chemotherapy administration.The duration of each HT session rangedfrom 70 to 90minutes,ensuring that the target temperature was maintained at or above 40 °C for at least 60 minutes. BSD-500 or BSD-2000 system was used based on the depth of the lesion.Survival rates were estimated, and acuteand late toxicity were reported

Results:

A total of 20 patients were included in the analysis, comprising 11males and 9 females, all with Performance Status ECOG 0-1. The mean age was 61 years (range, 34-87). Sixpatients had stage II disease, while the remaininghad stage III disease. Four patients had trunk lesions, andthe remaining had extremity lesions. The mean size of the treated tumor was 8.8 cm (range 2-20).Ninepatients (45%) had primary lesions, and 11(55%) had recurrent lesions. The mean number of HT sessionswas 7 (range 6-10). Eight patients receivedconcomitant chemotherapy, while4 patients received itsequentially.Grade 2 toxicity was observed in 5 patients (23.8%), with no cases of grade 3 4toxicity.Nineteen patients (95%) underwent surgery after completing the treatment, with all achievingnegative surgical margins except for one patient (5.2%) who had microscopic R1 margininvolvement.Complete pathological response was achieved in 7 out of 19 patients (36.8%). With a medianfollow-up of 21.3 months, disease progression occurred in 5 patients (25%), including 2 cases of localprogression and 3 cases of systemic progression (2 lung, 1 lung and liver). Median overall survival was notreached.Three -years overall survival resulted 82%. The median